514 related articles for article (PubMed ID: 32446864)
1. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".
Grimm MO; van der Heijden AG; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Caris C; Schipper RG; Witjes WPJ;
Eur Urol; 2020 Nov; 78(5):690-698. PubMed ID: 32446864
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial.
van Straten CGJI; Caris C; Grimm MO; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Witjes WPJ; van der Heijden AG; Kiemeney LALM
Eur Urol Open Sci; 2023 Oct; 56():15-24. PubMed ID: 37822514
[TBL] [Abstract][Full Text] [Related]
4. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
5. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
6. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
[TBL] [Abstract][Full Text] [Related]
8. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
9. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
11. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
[TBL] [Abstract][Full Text] [Related]
13. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
14. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
15. A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer.
Sood R; Sharma H; Sharma B; Parekh S; Pujari P; Shewale S
Urol Oncol; 2020 May; 38(5):433-439. PubMed ID: 32037199
[TBL] [Abstract][Full Text] [Related]
16. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
17. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
Chen S; Zhang N; Shao J; Wang X
Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
[TBL] [Abstract][Full Text] [Related]
18. Influence of the true number of Bacillus Calmette-Guérin instillations on the prognosis of non-muscle invasive bladder tumors.
Portillo JA; Madero R; Solsona E; Fernandez JM; Martínez-Piñeiro L; Palou J; Montesino M; Martínez-Piñeiro JA; Unda M;
Actas Urol Esp; 2014 Jun; 38(5):280-4. PubMed ID: 24529538
[TBL] [Abstract][Full Text] [Related]
19. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
20. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]